

CLAIM AMENDMENTS

1. (canceled)

2. (currently amended) A DNzyme which binds to GATA-3 mRNA and functionally inactivates it, which comprises:

- a catalytic domain with the nucleotide sequence
GGCTAGCTA CA AC GA GGCTAGCTACAACGA SEQ ID NO: 154 or a modified sequence with comparable biological effect, which cleaves the GATA-3 mRNA at every purine:pyrimidine binding site to which it is bonded,
- a right substrate binding domain adjoining the 3' end of the catalytic domain and
- a left substrate binding domain adjoining the 5' end of the catalytic domain, both substrate binding domains being respectively complementary to two regions of the GATA 3 mRNA so that they hybridize with the mRNA, and
- ~~[[are]]~~ which is active in vivo.

3. (currently amended) A DNzyme according to claim 2, which comprises the sequence hgd 40 GTGGATGGA GGCTAGCTACAACGA ~~GTCTTTGGAG~~ GTCTTGGAG SEQ ID NO: 40.

1 4. (previously presented) A DNzyme according to claim 2
2 which cleaves the catalytic domain of the GATA-3 mRNA at every
3 purine:uracil binding site.

1 5. (previously presented) A DNzyme according to claim 2
2 which is stabilized against decomposition within the organism by
3 introduction of a 3'-3' inversion.

1 6. (previously presented) A DNzyme according to claim 2
2 which is stabilized against decomposition within the organism by
3 introduction of modified nucleotides or nucleotide compounds.

1 7. (previously presented) A DNzyme according to claim 2
2 which includes an inverse thymidine on the 3' end and/or a FAM
3 label on the 5' end.

1 8. (previously presented) A medicament containing a
2 DNzyme according to claim 2 and a pharmaceutically acceptable
3 carrier.

Claims 9 through 16 (canceled).